

**Intake Specialist:** 1-866-776-6782

Fax: 800-815-6808

newreferral@promptcare.com

C-2024

| atient Name:  | DOB:   | Phone:  |   |  |  |  |
|---|--|---|---|--|--|--|
|   | City:  |   |   |  |  |  |
| . Please submit with  | ı form   |   |   |  |  |  |
|   | ce card  | ☑ History & physical 区  | Recent clinic notes                                 |  |  |  |
|   | to therapy (ex. factor levels, inhibitor te  |   |   |  |  |  |
| 2. Patient informatio Allergies: Is patient new to the spatient/caregives | n: □Male □Female Height:<br>□NKDA Line to<br>nis therapy? □No □Yes History of ing<br>r independent with infusing factor? □Ye<br>n needed (upcoming procedure, active b               | in/cm Weight ype: □PIV □PICC □Po nhibitor? □No □Yes: es □No Nursing ser | i: lbs/kg ort □No. of lumens vices needed? □Yes □No |  |  |  |
| . Diagnosis and Clini   | cal Information  |   |   |  |  |  |
| =   | red):  | ☐Factor X deficiency  |   |  |  |  |
| • •   | ctor VIII)   | □Factor XIII deficiency   |   |  |  |  |
| □Hemophilia B (Fa   | ctor IX) □Mild □Mod □Severe*   | ☐Glanzmann's Thrombasthenia   |   |  |  |  |
| □Von Willebrand,  | type □1 □2 □3 □*   | ☐Wiskott-Aldri  | ☐Wiskott-Aldrich Syndrome                           |  |  |  |
| ☐Factor VII deficie   | ncy  | □Other:   |   |  |  |  |
| . Prescription Inform   | nation   |   |   |  |  |  |
| Factor Replaceme  |  |   |   |  |  |  |
| ☐ Prophylaxis   | Product: Dos   | e:  | □units □VWF:RCo                                     |  |  |  |
|   | Give IV once every adays are   |   |   |  |  |  |
|   | Dispense: 1 month supply / Refill x □6 months □1 year □Other:  |   |   |  |  |  |
|   | Product: Dos   | e:  | □units □VWF:RCo                                     |  |  |  |
| ☐ On-Demand   | Give IV once every □hours □  |   |   |  |  |  |
| (PRN bleeding,  | Other:   |   |   |  |  |  |
| procedure, or as  | Dispense: total doses (OR: minor doses, major doses) / Refill x  |   |   |  |  |  |
| directed)   | Optional: Patient to keep doses in stock /   Keep at least 3 day supply in home  |   |   |  |  |  |
|   | Product: Dose  | e:  | □units □VWF:RCo                                     |  |  |  |
| ☐ Other   | IV Frequency / directions:   |   |   |  |  |  |
|   | Dispense: doses / Refill x Other:  |   |   |  |  |  |
| Administration  | ☑RN (or caregiver/patient if independent) to start peripheral IV or use existing CVC ☑Flush IV catheter with NS & heparin, if indicated, per PromptCare policy and procedure ☐Other: |   |   |  |  |  |
|   |  |   |   |  |  |  |
| Hemlibra (Emiciz  | umab) Therapy  |   |   |  |  |  |
|   | ☐ 3 mg/kg once weekly for 4 week   | s 🗆 Other:  |   |  |  |  |
| ☐ Loading Doses   | Dosing Weight kg Begin in  |   |   |  |  |  |
|   | <b>Dispense:</b> Quantity sufficient to cor  | mplete loading dose regi  | ment OR doses/No refill                             |  |  |  |
|   | ☐ 1.5 mg/kg weekly ☐ 3 mg/kg e   | every 2 weeks   | /kg every 4 weeks                                   |  |  |  |
| ☐ Maintenance   | □ Other:   |   |   |  |  |  |
| Dose  | Dosing weight: kg  | Dispense 1 month su   | pply / Refill x                                     |  |  |  |

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.



5.

6.

**Intake Specialist:** 1-866-776-6782

Fax: 800-815-6808

newreferral@promptcare.com

| Oral Medicat                                     | ions  |  |                |                                       |                         |                        |  |
|--|---|--|----------------|---------------------------------------|-------------------------|------------------------|--|
| Medication                                       | ☐ Aminocaproic acid 0.25 g/mL oral <b>solution</b> ☐ Aminocaproic acid <b>tablets</b> (☐500 mg or ☐1000 mg tablets) |  |                |                                       |                         |                        |  |
|  |   |  |                |                                       |                         |                        |  |
|  | ☐ Tranexamic acid 650 mg tablets  |  |                |                                       |                         |                        |  |
| Directions                                       | Give □mg □mg/kg □mL by mouth every hours as needed for bleeding,  |  |                |                                       |                         |                        |  |
|  | procedure, or as directed. Other:   |  |                |                                       |                         |                        |  |
| Quantity   | Dispense:   | tablets OR   |                |                                       |                         | / Refill x             |  |
| Desmopressi                                      | n (DDAVP)   |  |                |                                       |                         |                        |  |
| ☐ Subcutaneous injection (desmopressin 4 mcg/mL) |   | Give   | □mcg □mc       | g/kg □mL subcut                       | aneously, freque        | ency:                  |  |
|  |   | ☐ Give one dose 30 to 60 minutes prior to procedure  |                |                                       |                         |                        |  |
|  |   | ☐ Other:   |                |                                       |                         |                        |  |
|  |   | Dispensedose(s) / Refill x   |                |                                       |                         |                        |  |
|  |   |  |                |                                       |                         |                        |  |
| ☐ <b>Nasal spray</b> (desmopressin 1.5 mg/mL)    |   | <ul> <li>Dose based on patient weight as follows:</li> <li>Weight &lt;50 kg: administer 150 mcg (1 spray) in a single nostril</li> </ul> |                |                                       |                         |                        |  |
|  |   |  |                |                                       |                         |                        |  |
|  |   | Weight mcg)  | nt ≥50 kg: adm | inister 150 mcg (1                    | spray) in <b>eacn</b> n | ostril (total dose 300 |  |
|  |   | Directions:  |                |                                       |                         |                        |  |
|  |   |  | se as needed   | or bleeding, may                      | repeat after 8-12       | 2 hours then daily up  |  |
|  |   |  | um of 3 days   | , , , , , , , , , , , , , , , , , , , |                         | , , ,                  |  |
|  |   | ☐ Give one do  | se 2 hours pri | or to procedure                       |                         |                        |  |
|  |   | ☐ Other:   |                |                                       |                         |                        |  |
|  |   | Dispense 1 bottle / Refill x   |                |                                       |                         |                        |  |
| ☑ Dispense all                                   | medical supplies  | necessary for adm  |                |                                       |                         |                        |  |
| ☑Provide skill                                   | ed nursing to adm   | inister/teach prep   | aration and in | fusion of prescrib                    | ed medications          |                        |  |
|  |   |  |                |                                       |                         |                        |  |
| laverse React                                    | ion Orders (it app  | licable):  |                |                                       |                         | <del></del>            |  |
| rescriber Info                                   |   |  |                |                                       |                         |                        |  |
|  | ame:  |  |                |                                       |                         |                        |  |
|  |   |  |                |                                       | Zip:                    |                        |  |
|  |   | Fax:   |                |                                       |                         |                        |  |
| icense NO.:                                      |   | DEA NO.: _   |                | NPI: _                                |                         |                        |  |
| Physician  | Signature (Substi   | tution   | ate Phy        | sician Signature (                    | Dispense as Wri         | -                      |  |
| ,  | Permitted)  | -  | 1              |                                       | F                       | , = = = =              |  |

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.